Alpha 2.0
Login Register
» Authors » Kent Stewart

Kent Stewart

Explore the profile of Kent Stewart including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 118
Followers 0
Related Specialties
Biochemistry
Biomedical Engineering
Chemistry
Top 10 Co-Authors
Robert Mantei
Xumiao Zhao
Andrew Geyer
Michael D Wendt
Vincent L Giranda
Moshe Weitzberg
Todd W Rockway
Vered Klinghofer
Michael Morytko
Vicki L Nienaber
Published In
Bioorg Med Chem Lett
Annu Int Conf IEEE Eng Med Biol Soc
J Med Chem
Am J Clin Nutr
Antiviral Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Design and Applicability of a Mechanical Impedance Sensor for Vein Penetration Detection
Grown-Haeberli S, Montague-Alamin H, Slocum A, Hanumara N, Ramirez A, Connor J, et al.
Annu Int Conf IEEE Eng Med Biol Soc . 2020 Oct; 2020:4016-4019. PMID: 33018880
Intravenous needle insertion is typically conducted manually, with needles guided into vessels by feel while looking for a brief flash of blood. This process is imprecise and leads to mispositioned...
2.
Accuracy and optimization of a subcutaneous insulin model for less acute critical care patients
Thomas F, Dickson J, Pretty C, Stewart K, Fisk L, Shaw G, et al.
Annu Int Conf IEEE Eng Med Biol Soc . 2016 Jan; 2015:4435-8. PMID: 26737279
Extending safe, effective glycemic control to the general wards requires a simple approach using subcutaneous (SC) insulin. However, this approach can increase relative risk compared to intravenous insulin due to...
3.
Evaluation of a plasma insulin model for glycaemic control in intensive care
Dickson J, Thomas F, Pretty C, Stewart K, Shaw G, Chase J
Annu Int Conf IEEE Eng Med Biol Soc . 2016 Jan; 2015:4009-12. PMID: 26737173
Hyperglycaemia is a common complication in the intensive care unit (ICU), and is associated with worsened outcomes. Model-based insulin therapy protocols have been shown to be safe and effective in...
4.
Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors
Friedman M, Frank K, Aguirre A, Argiriadi M, Davis H, Edmunds J, et al.
Bioorg Med Chem Lett . 2015 Sep; 25(20):4399-404. PMID: 26372653
Previous work investigating tricyclic pyrrolopyrazines as kinase cores led to the discovery that 1-cyclohexyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine (12) had Jak inhibitory activity. Herein we describe our initial efforts to develop orally bioavailable analogs...
5.
Design and synthesis of tricyclic cores for kinase inhibition
Van Epps S, Fiamengo B, Edmunds J, Ericsson A, Frank K, Friedman M, et al.
Bioorg Med Chem Lett . 2012 Dec; 23(3):693-8. PMID: 23265875
Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand...
6.
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states
Berglund L, Lefevre M, Ginsberg H, Kris-Etherton P, Elmer P, Stewart P, et al.
Am J Clin Nutr . 2007 Dec; 86(6):1611-20. PMID: 18065577
Background: In subjects with a high prevalence of metabolic risk abnormalities, the preferred replacement for saturated fat is unresolved. Objective: The objective was to study whether carbohydrate or monounsaturated fat...
7.
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro
Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, et al.
Antiviral Res . 2007 Jun; 76(1):93-7. PMID: 17561278
Compound A-837093, a non-nucleoside HCV RNA-dependent RNA polymerase inhibitor, displayed nanomolar potencies against HCV genotypes 1a and 1b replicons. It also exhibited an excellent metabolic profile and achieved high plasma...
8.
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit
Backes B, Longenecker K, Hamilton G, Stewart K, Lai C, Kopecka H, et al.
Bioorg Med Chem Lett . 2007 Feb; 17(7):2005-12. PMID: 17276063
A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was...
9.
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors
Pei Z, Li X, Longenecker K, von Geldern T, Wiedeman P, Lubben T, et al.
J Med Chem . 2006 Jun; 49(12):3520-35. PMID: 16759095
A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity. X-ray crystallography data show that these inhibitors...
10.
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
Bruncko M, McClellan W, Wendt M, Sauer D, Geyer A, Dalton C, et al.
Bioorg Med Chem Lett . 2004 Dec; 15(1):93-8. PMID: 15582418
A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.